Bellast Ultra Plus 24mg — High-Density HA Filler for Deep Volumising & Severe Folds

Bellast Ultra Plus is DongkookPharma’s highest-density Bellast variant — 24 mg/mL cross-linked hyaluronic acid + 0.3% lidocaine, engineered with patented V-Matrix™ technology for deep tissue volumising. G’ value of 420 Pa supports cheek augmentation, severe nasolabial folds, and facial sculpting. BDDE residual under 1.5 ppm; FDA cleared and ISO 13485 certified.

DongkookPharma Co. Ltd.’s proprietary cross-linking process produces a stabilised HA gel matrix engineered for sustained tissue retention. The technology balances viscoelasticity (firmness for projection) with extrusion smoothness (easier injection through the 27G needle). The result: predictable handling, consistent gel distribution, and 12–18 months durability in deep dermis placement.

Non-animal hyaluronic acid produced by bacterial fermentation. Endotoxin levels controlled below international safety thresholds. Stringent manufacturing under GMP-certified conditions minimises BDDE residue, heavy metals, and protein contaminants — reducing the risk of post-injection inflammation, granuloma formation, or hypersensitivity reactions in suitable patient profiles.

Non-animal hyaluronic acid produced by bacterial fermentation, cross-linked using DongkookPharma Co. Ltd.’s V-Matrix™ Patented Cross-Linking technology. The cross-linking process creates a stable, durable gel matrix that resists rapid enzymatic breakdown in tissue. Phosphate-buffered saline carries the gel at near-physiological pH.

Premixed local anaesthetic at the industry-standard 0.3% concentration. Reduces injection-site discomfort and eliminates the need for on-site mixing with separate lidocaine vials. The lidocaine itself wears off within hours of injection and does not affect long-term gel duration.

Cheek Augmentation

Primary indication. Deep subcutaneous and supraperiosteal placement for midface volumising. The 24 mg/mL HA concentration and V-Matrix™ structure deliver sustained projection in the zygomatic region.

Severe Nasolabial Folds

Pronounced nose-to-mouth folds requiring structural fill. High G’ value (420 Pa) maintains correction over time.

Chin Augmentation

Chin projection and jawline definition. Off-label use; supraperiosteal placement is standard for non-surgical chin contouring.

Deep Marionette Lines

Severe oral commissure-to-jaw furrows in older patients. Ultra Plus’s firmness delivers structured correction where lighter variants would dissipate.

Manufacturer

• Brand: Bellast
• Company: DongkookPharma Co. Ltd.
• Country: South Korea
• Established: 1968

Formula

• HA Source: Non-animal bacterial fermentation
• HA Concentration: 24 mg/mL
• Lidocaine: 0.3% (3 mg/mL) premixed
• Cross-linking: V-Matrix™ Patented Cross-Linking

Performance

• Duration: 12–18 months
• Injection Depth: Deep dermis · subcutaneous
• Recommended Needle: 27G
• Last Reviewed: May 2026

Approval & Storage

• Approvals: KFDA registered · FDA cleared · ISO 13485 · CE marked
• Packaging: 1 × 1 mL pre-filled syringe + 2 × 27G needles
• Storage: 2–25 °C, do not freeze
• Shelf life: 24 months unopened

Bellast Ultra Plus 24mg High-Density HA Filler is a prescription medical device for use only by licensed aesthetic practitioners. Common reactions include injection-site bruising, swelling, redness, and tenderness — generally resolving within days. Deep placement (subcutaneous and supraperiosteal layers) involves heightened anatomical awareness of facial vasculature; practitioners require access to hyaluronidase for emergency dissolution. Like all hyaluronic acid dermal fillers, treatment carries rare but serious vascular complication risks. Contraindicated in patients with known hypersensitivity to hyaluronic acid or lidocaine, active skin infection at the treatment site, pregnancy, or breastfeeding. Full contraindications, vascular complication protocols, aftercare, and emergency guidance are detailed on the dermal filler safety page.